Vivos Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 127/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vivos Therapeutics Inc's Score
Industry at a Glance
Industry Ranking
127 / 208
Overall Ranking
296 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.500
Target Price
+154.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Vivos Therapeutics Inc Highlights
StrengthsRisks
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.03M.
Fairly Valued
The company’s latest PE is -1.11, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 815.76K shares, decreasing 2.60% quarter-over-quarter.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Ticker SymbolVVOS
CompanyVivos Therapeutics Inc
CEOHuntsman (R. Kirk)
Websitehttps://vivos.com/
FAQs
What is the current price of Vivos Therapeutics Inc (VVOS)?
The current price of Vivos Therapeutics Inc (VVOS) is 1.970.
What is the symbol of Vivos Therapeutics Inc?
The ticker symbol of Vivos Therapeutics Inc is VVOS.
What is the 52-week high of Vivos Therapeutics Inc?
The 52-week high of Vivos Therapeutics Inc is 7.950.
What is the 52-week low of Vivos Therapeutics Inc?
The 52-week low of Vivos Therapeutics Inc is 1.925.
What is the market capitalization of Vivos Therapeutics Inc?
The market capitalization of Vivos Therapeutics Inc is 16.29M.
What is the net income of Vivos Therapeutics Inc?
The net income of Vivos Therapeutics Inc is -11.14M.
Is Vivos Therapeutics Inc (VVOS) currently rated as Buy, Hold, or Sell?
According to analysts, Vivos Therapeutics Inc (VVOS) has an overall rating of Buy, with a price target of 5.500.
What is the Earnings Per Share (EPS TTM) of Vivos Therapeutics Inc (VVOS)?
The Earnings Per Share (EPS TTM) of Vivos Therapeutics Inc (VVOS) is -1.772.